The Outcome of Tisagenlecleucel (Tisa-Cel) Vs Axicabtagene Ciloleucel (Axi-Cel) CD-19 CAR-T Cell Therapy in Relapsed/Refractory NHL: Real World Data from a Single Institution Experience

Non-Hodgkin lymphoma (NHL) in Saudi Arabia exhibits an incidence rate of 6.1%, with estimated age adjusted incidence is 6/100,000, presenting at an advanced stage up to 40% stage IV. The CD 19 chimeric antigen receptor (CAR) T-cell therapy targets and eliminates CD19-expressing B cells and shows efficacy against B-cell lymphomas.

Source: Biology of Blood and Marrow Transplantation - February 1, 2024 Category: Hematology Authors: Reem Alasbali, Abdulrahman Nasiri, Alfadil Haroon Adam, Saud Alhayli, Naeem Chaudhri, Alfadel Alshaibani, Abdulwahab Albabtain, Hadeel Samarkandi, Ayman Saad, Abdullah Alamer, Tusneem A Elhassan, Hazzaa Alzahrani, Syed O Ahmed, Walid K. Rasheed, Riad El F Tags: 496 Source Type: research